iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
To evaluate executive pay at a public biotech company, read its latest definitive proxy statement (DEF 14A), then compare what executives were offered with what they actually earned, vested or forfeited. Check the goals and award terms—not just the headline grant value—and account for the company’s development stage, share usage and potential dilution. No single proxy table can establish whether compensation is “fair”; the useful answer comes from how the pieces fit together over time.
Which parts of the proxy statement matter?
Start with the Compensation Discussion and Analysis (CD&A), which explains the compensation committee’s stated objectives and decisions. Then use the tables and footnotes to test that explanation against reported amounts and award outcomes.
- Summary Compensation Table: Reports compensation under SEC disclosure rules, including salary, bonus, stock and option awards, and total compensation. Equity amounts here generally reflect grant-date values, not cash received or the eventual value of the awards.
- Grants of Plan-Based Awards: Shows award grants and, for applicable incentive plans, threshold, target and maximum opportunities. Read its footnotes for grant terms and valuation details.
- Outstanding Equity Awards at Fiscal Year-End: Shows unvested awards and outstanding options, including option exercise prices and expiration dates.
- Option Exercises and Stock Vested: Helps distinguish awards granted from options exercised and stock that vested during the year.
- Potential Payments Upon Termination or Change in Control: Shows how severance, vesting acceleration and other arrangements may affect potential payouts.
- Pay Versus Performance: Provides a standardized comparison of compensation measures and performance over time, subject to eligibility and calculation rules.
Look beyond the table labels. The CD&A, footnotes and award agreements may explain vesting, performance conditions, committee discretion, settlement and forfeiture provisions that a summary number cannot show.
The Tool Desk
Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →How do the reported pay figures differ?
Keep three concepts separate when comparing executive compensation:
#1 Best Overall
- Grant-date compensation: The reported value assigned to an award when granted. It is an accounting-based value, not a promise of cash or the amount the executive will ultimately receive.
- SEC-defined “compensation actually paid”: A prescribed calculation that starts with Summary Compensation Table totals and adjusts for specified pension and equity-award values. Despite its name, it is not simply cash paid to an executive.
- Realized or realizable compensation: These terms are used in company disclosures to discuss value received from vested or exercised awards, or the estimated value of holdings at a particular date. Check the company’s definition, valuation date and included awards before comparing it with target pay.
A large grant-date value can become worth more, less or nothing, depending on performance, vesting and the stock price. Compare target opportunity with actual cash payouts and equity earned or forfeited across multiple years, using consistent definitions.
How do options, RSUs and PSUs work differently?
| Award type | How value is determined | What to inspect |
|---|---|---|
| Stock options | An option generally has no intrinsic value when the share price is below its exercise price. It can gain value if the share price rises above that price, subject to vesting and other terms. | Exercise price, vesting schedule, expiration, repricing provisions and current share price relative to the strike. Grant-date fair value is not the same as eventual value. |
| Restricted stock units (RSUs) | RSUs can retain stock-linked value as they vest, even when company performance is weak. Time-based vesting can support retention. | Number of shares, vesting period, settlement, forfeiture conditions and any dividend equivalents. |
| Performance stock units (PSUs) or performance shares | Payout depends on specified results; an award can pay zero if threshold goals are missed. | Metrics and weights, performance period, threshold/target/maximum levels, payout curve, peer set, absolute-return gates, caps and committee discretion. |
For each award, ask what happens when results fall below threshold, meet target or exceed maximum. A PSU label alone does not show whether the goals are demanding or well connected to company strategy.
How should you assess annual cash bonuses and performance goals?
Annual incentive plans deserve the same scrutiny as equity. Identify the weighting of corporate and individual objectives, the performance period, threshold and maximum payouts, and any adjustments for unusual items. Compare the goals disclosed with actual achievement and the committee’s explanation of the resulting payout.
Biotech plans may use shareholder returns or financial outcomes alongside clinical, pipeline, regulatory, commercial, business-development or other strategic milestones. Judge whether a goal was set in advance, defined clearly enough to assess, measured over an appropriate period and certified by the committee. An operational milestone can matter to the business without necessarily creating shareholder value; ask whether the plan’s payout responds meaningfully to both success and failure.
Development timelines make the company’s stage essential context. A clinical-stage company may emphasize pipeline progress while revenue and earnings remain limited. A company beginning commercialization may add product revenue or other financial measures. Compare goals with the business the company was actually operating during the award period.
How can you judge peer benchmarking and pay mix?
Peer comparisons are useful only when the selected companies compete for reasonably similar talent or capital. Examine the peer group’s stage, size, therapeutic focus, geography and business model. In the CD&A, look for how the committee used peer data and any compensation consultant’s work—not simply whether a peer group existed.
Rank #3
For each named executive officer, map target compensation into fixed salary, annual variable cash and long-term equity. Then compare the target mix with actual payouts and equity outcomes. A stated market-median philosophy is a reference point, not proof that the resulting package is appropriate for the company or that performance conditions are strong.
What does the SEC Pay Versus Performance table tell you?
Item 402(v) of Regulation S-K requires eligible companies to present a multi-year comparison. Under the SEC’s October 11, 2022 small-entity compliance guide, the table generally covers five completed fiscal years for registrants other than smaller reporting companies (SRCs), and three years for SRCs. The guide identifies exclusions including foreign private issuers, registered investment companies and emerging growth companies.
The table reports total compensation and SEC-defined compensation actually paid for the principal executive officer (PEO), plus an average for the other named executive officers. Required comparisons include company cumulative total shareholder return (TSR), net income, and—except for SRCs—peer-group TSR and a company-selected financial measure. Non-SRCs also disclose three to seven important financial performance measures. The disclosure is tagged in Inline XBRL.
Rank #4
Use the table to spot patterns and then read the company’s explanation and award terms. Its standardized calculations do not show every dimension of scientific execution, cash compensation received or the difficulty of particular goals. It is context for judgment, not a stand-alone verdict on whether executives were paid well.
How should you account for biotech examples and company transitions?
Proxy examples show different design choices, not an industry-wide template. Adaptimmune Therapeutics plc’s 2026 proxy describes an expanded 2026 PSU program for all executive officers, with a standard equity mix of 50% RSUs and 50% PSUs. The two PSU measures—relative TSR and MRD revenue CAGR—each carry a 50% weight over a three-year period. The proxy also says the company’s most recent say-on-pay vote received 98.8% support. These are company-reported details, not evidence by themselves that the goals or package are optimal.
Free tools Windows power users keep installed
One-click scans. No signup required.
Incyte’s 2026 proxy describes annual cash incentives tied to commercial, R&D, business-development and ESG goals, alongside time-based and performance-based equity. Krystal Biotech’s 2026 proxy describes salary, annual performance-based cash bonuses and long-term equity; it says the committee considers peer information, consultant input, outstanding executive equity, burn rate and potential dilution. The same proxy explains that its options provide no value if the common-stock price is below the exercise price.
A transition to commercialization can change which measures are informative. Cytokinetics’ 2026 proxy reports its first drug approval in December 2025 and commercial sales beginning in January 2026; it also says the company had no company-selected financial measure in its pay-versus-performance disclosure. That example illustrates why pipeline and strategic context may matter alongside near-term financial comparisons during a transition.
Biogen’s 2026 proxy reports that certain performance-share cycles expired with no value after threshold goals were not achieved, and discusses changes to performance-share design following shareholder feedback. It also compares CEO realizable pay with target pay: for the period from the CEO’s 2022 hire through the end of 2025, the company says realizable pay was 48% lower than target pay awarded. The proxy reports a $16.8 million grant-date value for the CEO’s new-hire PSUs, which the company says expired unearned in December 2025. These figures describe that company’s awards and stated period; they are not biotech-wide benchmarks.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How do dilution and shareholder votes fit into the analysis?
Executive grants use shares or options that can affect ownership and dilution. Consider more than the dollar value assigned to one executive’s awards:
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
- Shares granted and the available share pool.
- Share usage or burn rate, as disclosed by the company.
- Outstanding unvested awards and potential dilution from outstanding equity.
- Whether new grants serve a stated retention or performance purpose in light of existing holdings.
Check the say-on-pay vote and whether the board describes changes in response to shareholder feedback. A vote provides context about shareholder support; it does not replace analysis of goals, award outcomes or dilution.
A practical checklist for a named company
- Open the issuer’s latest definitive proxy statement and note its fiscal year, company stage and executive names.
- Read the CD&A, then compare its stated objectives with the Summary Compensation Table and plan-award tables.
- For each executive, separate salary, target and paid annual cash incentives, and long-term awards. Track what vested, was exercised, earned or forfeited over several years.
- For every material award, record its type, performance period, vesting conditions, goals, thresholds and treatment on termination or change in control.
- Assess whether performance measures and peer companies fit the company’s stage, business and talent market. Note how committee discretion or adjustments affected results.
- Review the Pay Versus Performance table alongside the company’s explanation, remembering that “compensation actually paid” is a prescribed valuation measure rather than cash received.
- Inspect share usage, existing unvested awards, potential dilution, say-on-pay support and any board response to shareholder feedback.
Issuer proxies are board and management disclosures, not independent verification that goals were difficult or pay was fair. Treat a company’s rationale as one input, and use the underlying tables, footnotes and award terms to assess what the plan rewarded and what shareholders bore.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
